Comparison of Drug-Eluting Stents Versus Bare-Metal Stents for Treating ST-Segment Elevation Myocardial Infarction
Mehdi H. Shishehbor, DO, MPH,
Reza Amini, MD,
Leonardo P.J. Oliveria, MD,
Inder M. Singh, MD, MS,
Peter Kelly, MD,
Deepak L. Bhatt, MD,
Samir R. Kapadia, MD,
Stephen G. Ellis, MD,
Patrick L. Whitlow, MD,
Sorin J. Brener, MD*
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.
View larger version (11K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Kaplan-Meier Curves for Overall Nonpropensity-Matched Patients According to Stent Type (n = 699)
Note freedom from all-cause mortality and target lesion revascularization among those receiving drug-eluting compared with bare-metal stents.
|
|
View larger version (11K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Kaplan-Meier Curves for Overall Propensity-Matched Patients According to Stent Type (n = 480)
Note freedom from all-cause mortality and target lesion revascularization among those receiving drug-eluting compared with bare-metal stents.
|
|
|
